Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT04664153) tested a topical (applied to the skin) treatment called PF-07038124 0.01% ointment against a vehicle (a plain ointment with no active ingredient, similar to a placebo) in two separate groups of people: those with atopic dermatitis (eczema) and those with plaque psoriasis. A total of 104 people started the trial — 34 received the vehicle and 36 received the active ointment for eczema, while 17 received the vehicle and 17 received the active ointment for psoriasis. All treatments were applied once daily. The trial measured changes in standard skin scoring tools over 6 weeks — a higher score on these tools means more severe disease, and a lower score means less severe disease. The reported data shows that for the eczema group, participants using the vehicle ointment had an average reduction of 35.5% in their eczema severity score (called EASI) from the start of the trial to week 6, while those using PF-07038124 had an average reduction of 74.9%. For psoriasis, the vehicle group's severity score (called PASI) changed by +0.1 points (essentially no change) from the start of the trial to week 6, while the PF-07038124 group's score reduced by 4.8 points. Among the secondary measurements reported for eczema, 44.4% of participants using PF-07038124 reached a score of "clear" or "almost clear" on a separate 5-point doctor's rating scale at week 6, compared with 8.8% in the vehicle group. By week 6, 61.1% of those using PF-07038124 had achieved at least a 75% improvement in their eczema severity score, compared with 20.6% in the vehicle group. The reported data also shows that for the self-reported itch score (rated from 0 to 10), 41.2% of PF-07038124 eczema participants reported a meaningful reduction in itch (defined as a drop of 4 or more points) by weeks 4 and 6, compared with 6.9% and 13.8% respectively in the vehicle group at those same time points. These figures describe only what was measured and recorded in this trial, and no conclusions about broader use should be drawn from them alone. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 38117526) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Psoriasis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
For Atopic Dermatitis (eczema):
- You have been diagnosed with atopic dermatitis (eczema) for at least 3 months
- Your eczema has been rated as mild or moderate by a doctor using a standard assessment scale
- Your eczema covers between 5% and 20% of your body surface area
For Plaque Psoriasis:
- You have been diagnosed with plaque psoriasis for at least 6 months
- Your psoriasis has been rated as mild or moderate by a doctor using a standard assessment scale
- Your psoriasis covers between 5% and 15% of your body surface area
Who may not be able to join:
- You have other skin conditions that could affect how the treatment works or how results are measured
- You currently have or recently had a serious, worsening, or uncontrolled condition affecting the kidneys, liver, blood, stomach/gut, metabolism, hormones, lungs, heart, or nervous system
- You have another significant medical or mental health condition that the doctor believes could make participation unsafe or unsuitable
- You have had thoughts or behaviours related to suicide in the past year, or are currently experiencing them (confirm with trial site)
- You have abnormal laboratory test results that could increase the risks of taking part (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Pfizer CT.gov Call Center, Pfizer
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
2 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 6 for AD Participants; Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 6 for Plaque Psoriasis Participants
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.